NO20005672L - Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet - Google Patents

Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet

Info

Publication number
NO20005672L
NO20005672L NO20005672A NO20005672A NO20005672L NO 20005672 L NO20005672 L NO 20005672L NO 20005672 A NO20005672 A NO 20005672A NO 20005672 A NO20005672 A NO 20005672A NO 20005672 L NO20005672 L NO 20005672L
Authority
NO
Norway
Prior art keywords
antigen
attenuated salmonella
constitutively expressing
salmonella mutants
same
Prior art date
Application number
NO20005672A
Other languages
English (en)
Other versions
NO20005672D0 (no
Inventor
Fernando R Noriega
Marcelo Sztein
Myron M Levine
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of NO20005672D0 publication Critical patent/NO20005672D0/no
Publication of NO20005672L publication Critical patent/NO20005672L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255Salmonella (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/831Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/879Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20005672A 1998-05-13 2000-11-10 Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet NO20005672L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/076,761 US6190669B1 (en) 1998-05-13 1998-05-13 Attenuated mutants of salmonella which constitutively express the Vi antigen
PCT/US1999/006554 WO1999058146A1 (en) 1998-05-13 1999-04-30 ATTENUATED MUTANTS OF SALMONELLA WHICH CONSTITUTIVELY EXPRESS THE Vi ANTIGEN

Publications (2)

Publication Number Publication Date
NO20005672D0 NO20005672D0 (no) 2000-11-10
NO20005672L true NO20005672L (no) 2001-01-15

Family

ID=22134022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005672A NO20005672L (no) 1998-05-13 2000-11-10 Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet

Country Status (16)

Country Link
US (1) US6190669B1 (no)
EP (1) EP1076566B1 (no)
JP (1) JP4363782B2 (no)
AT (1) ATE333285T1 (no)
AU (1) AU754795B2 (no)
CA (1) CA2328056C (no)
DE (1) DE69932425T2 (no)
DK (1) DK1076566T3 (no)
ES (1) ES2268864T3 (no)
HU (1) HUP0101747A3 (no)
MX (1) MXPA00011075A (no)
NO (1) NO20005672L (no)
NZ (1) NZ508110A (no)
PL (1) PL192378B1 (no)
WO (1) WO1999058146A1 (no)
ZA (1) ZA200006381B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
MXPA00012796A (es) * 1999-12-28 2002-05-23 Akzo Nobel Nv Vacuna de salmonella.
PL359293A1 (en) * 2000-04-20 2004-08-23 University Of Maryland, Baltimore Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
WO2004001020A2 (en) * 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and means to promote gut absorption
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
EP1941024B1 (en) * 2005-10-28 2013-07-31 University of Maryland, Baltimore Attenuated salmonella enterica serovar paratyphi a and uses thereof
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062371A2 (en) * 2005-11-23 2007-05-31 University Of Maryland, Baltimore Live vector vaccine and uses thereof
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
BRPI0621490A2 (pt) * 2006-03-20 2011-12-13 Univ Bruxelles cepa mutante atenuada de uma bactéria infectante de espécies veterinárias, vacina para imunização de espécies veterinárias contra uma infecção bacteriana, método para imunizar uma espécie veterinária contra uma infecção bacteriana, uso de uma cepa mutante atenuada e método para distinção sorológica entre animais vacinados e animais infectados por uma cepa alelo-selvagem
EP2004802A1 (en) * 2006-03-20 2008-12-24 Vrije Universiteit Brussel Live attenuated salmonella vaccine
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
EP3351268B1 (en) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
US20110020399A1 (en) * 2007-04-16 2011-01-27 University Of Maryland, Baltimore Vaccines and Immunomodulatory Therapies for Tularemia
US9125854B2 (en) * 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
NO2525817T3 (no) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
WO2013126622A1 (en) * 2012-02-24 2013-08-29 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
KR20240054373A (ko) * 2021-09-10 2024-04-25 리젠츠 오브 더 유니버시티 오브 미네소타 종양의 비독성 콜로니화를 위해 조작된 살모넬라

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5783196A (en) 1996-04-09 1998-07-21 University Of Maryland At Baltimore Gua mutants of shigella spp. and vaccines containing the same

Also Published As

Publication number Publication date
AU3740599A (en) 1999-11-29
EP1076566A4 (en) 2005-01-05
PL344593A1 (en) 2001-11-05
HUP0101747A2 (hu) 2001-09-28
ZA200006381B (en) 2002-02-07
PL192378B1 (pl) 2006-10-31
ATE333285T1 (de) 2006-08-15
NZ508110A (en) 2002-10-25
AU754795B2 (en) 2002-11-28
CA2328056A1 (en) 1999-11-18
WO1999058146A1 (en) 1999-11-18
EP1076566A1 (en) 2001-02-21
ES2268864T3 (es) 2007-03-16
MXPA00011075A (es) 2002-04-24
NO20005672D0 (no) 2000-11-10
DE69932425T2 (de) 2007-03-08
HUP0101747A3 (en) 2002-03-28
JP4363782B2 (ja) 2009-11-11
EP1076566B1 (en) 2006-07-19
US6190669B1 (en) 2001-02-20
DK1076566T3 (da) 2006-11-13
DE69932425D1 (de) 2006-08-31
JP2002514398A (ja) 2002-05-21
CA2328056C (en) 2010-07-06

Similar Documents

Publication Publication Date Title
NO20005672D0 (no) Svekkede Salmonella-mutanter som uttrykker Vi-antigenet konstitutivt
EP1032417A4 (en) BACTERIAL VACCINES CONTAINING ATTENUATED AUXOTROPHIC STRAINS OF LISTERIA EXPRESSING HETEROLOGIC ANTIGENS
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DK142391A (da) Indretning til tilberedning, servering og opbevaring af f.eks. madvarer
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
DZ1763A1 (fr) Composition vaccinantes.
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
AU9094191A (en) Recombinant avirulent salmonella antifertility vaccines
DK1326633T3 (da) Sammensætning omfattende immunogene mikropartikler
MX9203852A (es) Composicion selladora acrilica mejorada, y metodos relacionados con la misma.
TR200401569T4 (tr) Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
NO910739D0 (no) Sementeringsmateriale for olje, gass- og vannbroenner.
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
DE69105285D1 (de) Gegen Wärme vakuumisolierter Behälter.
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
DE3873278D1 (de) Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
FI911258A0 (fi) Foer kylmaskin, i synnerhet foer hushaollskylskaop avsedd plaotkondensator.
FI900713L (fi) Trycksaeker skalkonstruktion foer undervattensteknik, i synnerhet foer djuphavsteknik.
AU3487799A (en) Improved live attenuated viruses for use as vectors or vaccines
FI912699A0 (fi) Expenderingskropp, saerskilt foer massautloppslaodan i en pappersmaskin.
SU979504A1 (ru) Щтамм НАГ-фага 93,Ф-98,лизирующий НАГ-вибрионы 0-8 серотипа
IT8223644A0 (it) Serracavo, particolarmente per elettrodomestici o simili.
IT1238603B (it) Valvola cardiaca artificiale, con elevatissimo grado di sicurezza
WO1999027955A3 (en) Treatment of established chronic infections and cancers

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application